Virchows Archiv

, Volume 464, Issue 1, pp 79–83 | Cite as

HPV typing of high-grade dysplasia (CIN III) in cone biopsies of 38 HPV-vaccinated women

  • Ondrej Ondič
  • Jana Kašpírková
  • Ondřej Májek
  • Iva Kinkorová
Original Article


HPV-vaccinated women develop CIN III very rarely. We have identified a study group of 38 such patients and showed that a specific HPV genotype prevalence in those cases equals the prevalence of HPV genotypes in CIN III present in the general Czech population. In all cases, CIN III was diagnosed within 3 years after having completed the HPV vaccination. We conclude that dysplasia was present before the vaccination in those women. A history of abnormal pre-vaccination PAP smear result (present in 78 % of women in the study group) and age of over 17 by the time of vaccination completion (97 % of women in the study group) are identified as probable factors increasing the risk of CIN III development after HPV vaccination.


Cervix Dysplasia CIN III HPV Vaccination 


  1. 1.
    van Dongen JJ, Langera AW, Bruggemann M et al (2003) Design and standardisation of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 17:2257–2317PubMedCrossRefGoogle Scholar
  2. 2.
    Kašpírková J, Ondič O, Černá K, Skálová A (2013) The testing strategy for detection of biologically relevant infection of human papillomavirus in head and neck tumors for routine pathological analysis. Cesk Patol 49(1):29–34PubMedGoogle Scholar
  3. 3.
    Hagmar B, Johansson B, Kalantari M, Petersson Z, Skyldberg B, Walaas L (1992) The incidence of HPV in a Swedish series of invasive cervical carcinoma. Med Oncol Tumor Pharmacother 9(3):113–117PubMedGoogle Scholar
  4. 4.
    Tachezy R, Smahelova J, Salakova M, Arbyn M, Rob L et al (2011) Human papillomavirus genotype distribution in Czech women and men with diseases etiologically linked to HPV. PLoS ONE. doi:10.1371/journal.pone.0021913 Google Scholar
  5. 5.
    Szarewski A et al (2012) Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15–25 years with and without serological evidence of previous exposure to HPV-16/18. Int J Cancer 131(1):106–116PubMedCrossRefGoogle Scholar
  6. 6.
    Geraets D et al (2012) Detection of rare and possibly carcinogenic human papillomavirus genotypes as single infections in invasive cervical cancer. J Pathol 228(4):534–543. doi:10.1002/path.4065 Google Scholar
  7. 7.
    Schiffman M, Clifford G, Buonaguro FM (2009) Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect Agent Cancer. doi:10.1186/1750-9378-4-8 PubMedCentralPubMedGoogle Scholar
  8. 8.
    Bonanni P et al (2011) An overview on the implementation of HPV vaccination in Europe. Hum Vaccines 7:128–135CrossRefGoogle Scholar
  9. 9.
    Castle PE, Gravitt PE, Wentzensen N, Schiffman M (2012) A descriptive analysis of prevalent vs incident cervical intraepithelial neoplasia grade 3 following minor cytologic abnormalities. Am J Clin Pathol 138(2):241–246PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Ondrej Ondič
    • 1
    • 2
  • Jana Kašpírková
    • 3
  • Ondřej Májek
    • 4
  • Iva Kinkorová
    • 2
  1. 1.Šikl’s Department of Pathology, University Hospital, Faculty of MedicineCharles UniversityPilsenCzech Republic
  2. 2.Bioptická laboratoř s.r.o.PilsenCzech Republic
  3. 3.Department of GeneticsBioptická laboratoř s.r.o.PilsenCzech Republic
  4. 4.Institute of Biostatistics and AnalysesMasaryk UniversityBrnoCzech Republic

Personalised recommendations